Compared with previous meta-analyses,25–27 our study confirms the cardiovascular protective effects of GLP-1 RAs in individuals with T2D and further extends prior work by incorporating the most recent trials, increasing the overall sample size with a focus on T2D, and identifying important baseline characteristics—BMI and age—as significant modifiers of cardiovascular benefit. Here, GLP1R is linked to type 2 diabetes mellitus.